

CARDIFF AND VALE UNIVERSITY HEALTH BOARD  
CORPORATE MEDICINES MANAGEMENT GROUP  
**NOTES OF MEETING HELD ON THURSDAY 6<sup>th</sup> October 2022**

Present: Clinical Director Pharmacy and Medicines Management (Chair),  
Clinical Board Pharmacist Mental Health, Clinical Board Pharmacist  
Specialist Services, Lead Medicines Access Pharmacist, Clinical Board  
Pharmacist PCIC, Clinical Board Pharmacist Surgery, LMC rep1,  
Clinical Board Pharmacist Medicine, Clinical Director Mental Health  
Clinical Board, Deputy Executive Medical Director, Executive Medical  
Director, LMC rep2, Clinical Director Medicine Clinical Board.

Apologies: Assistant Director Finance, Associate Medical Director Primary Care,  
Clinical Director C&W Clinical Board

1. **Welcome**

2. **Declarations of interest**

Nil

3. **Notes of last meeting (1/9/22)**

Accepted as accurate

4. **Matters arising**

- a) *Cariprazine for schizophrenia in adults IPD*  
XX presented amended IPD - Approved for implementation

5. **Items for discussion/approval**

- a) *Actinic Keratosis Guidelines*  
This is an outline of the treatment pathway which has been approved by  
the Medicine Clinical Board and the PCIC Clinical Board. A Health  
Pathway is being developed with the interface GP for Dermatology, which  
will support this using Primary Care and Education. Endorsed by cMMG.

6. **Financial position – medicines management**

- a) *Finance position update month 6*  
The Operational Overspend is just over a million and this is mainly  
down to PCIC. Large number of issues going on in prescribing with  
forecast overspend of just under 5 million. Significant issues are  
volume growth (just under 3%) and average price per item is around  
£8.00 - £8.12. NCSO's running at nearly £400,000 a month and there  
is no evidence of that coming down.  
140 items now have concessions added to them with a planned  
category M price increase coming in also. Covid related expenditure is  
at just under £600,000, and again most of this is related to PCIC.  
Savings plans are £3.2 million and the Corporate savings target is  
£650,000 which has been incorporated into Clinical Boards position  
this month.

## 7. IPDs and pathways to note

### a) *Pretomanid for Multi-Drug resistant mycobacterium tuberculosis*

This is an antibiotic used in multi-drug, used for resistant Mycobacterium tuberculosis and is recommended by the World Health Organisation. It will not be looked at by NICE or AWMSG, due to the small number of patients treated with it in the UK. It decreases the treatment from 12-18 months to 6 months, which introduces a cost saving element but also decreases the number of agents needed to be used to treat the condition. On micro recommendation only.

Approved for implementation

### b) *Tirbanibulin ointment for actinic keratosis*

This is supported by the actinic keratosis guidelines.

It has been approved by Medicine and PCIC Clinical Board.

Approved for Implementation.

## 8. Formulary update

### a) Risankizumab in psoriatic arthritis

This is currently on the formulary to treat psoriatic arthritis so this SBAR represents a licensed extension which has been approved by NICE. Cost to organisation sits in 3<sup>rd</sup> line and is comparable to agents already being used. cMMG suggested consideration of a pathway being developed due to the increasing number of agents approved.

Endorsed by cMMG.

### b) Medicines for ratification

4 new items have been approved this month. There is a supply problem with Calcichew and currently Ad-Cal is being looked at as an alternative, which seems to be the most cost effective. Added to the formulary as on offline agreement with the Clinical Board Pharmacists

## 9. Other items to note

None

## 10. Any other business

XX - Electronic prescription and medicines administration project is looking for lead clinical sessions so an expression of interest is going out today.

XX – query progress in Slenyto discussions. XX has had conversations with AWMSG who would not be reviewing their decision. XX to discuss within

C&W MMG though limited prescribing happening. XX to set up a meeting with XX, XX and a paediatric consultant to discuss higher principles further.

XX – update current position on treatments for Wet AMD due to current change to biosimilar Ongavia and new NICE approved drug faricimab. Ophthalmologists keen on the new drug – advised needs to go through Surgery MMG then cMMG for ratification. XX to draft paper for SMMG.

XX – query on ongoing GLP shortages, XX advised paper due to be issued today/tomorrow advising actions to take.

Date of next meeting **Thursday 3<sup>rd</sup> November** 2022, 8.30 – 9.30, via TEAMS. Chief Executive has been invited.